EPIGENOMICS AG Inactive Instrument
Epigenomics AG Stock Xetra
Equities
DE000A1K0516
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.42M 1.54M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | - 0 | EV / Sales 2024 * | - |
| Net cash position 2024 * | 2.48M 2.69M | Net cash position 2025 * | 1.39M 1.5M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.81
x | P/E ratio 2025 * |
-2.83
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Frederic Hilke
IRC | Investor Relations Contact | - | - |
Annett Dietrich
HRO | Human Resources Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Helge Lubenow
CHM | Chairman | 56 | 16-05-24 |
Jochen Hummel
BRD | Director/Board Member | 54 | Feb. 04 |
Alexander Link
BRD | Director/Board Member | 53 | 20-05-31 |
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-05-28
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -31.06% | 9.3B | |
| -8.43% | 3.1B | |
| +27.31% | 2.87B | |
| -14.31% | 2.17B | |
| -18.94% | 1.75B | |
| +73.13% | 1.5B | |
| +30.25% | 807M | |
| -1.97% | 759M | |
| -26.73% | 532M |
